Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroapiXPAR:EAPI -0.71%54 Operating Cash Flow per Share is €1.35 as of Dec. 2025. GuruFocus rates XPAR:EAPI with a GF Score™ of 54/100 and a GF Value™ of €2.84 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 763 Drug Manufacturers companies, Euroapi ranks better than 84.53% on this metric.
Euroapi's operating cash flow per share for the
six
months ended in Dec. 2025 was €1.16.
Euroapi's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.35.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Euroapi was 4.20% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 42.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 2.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Euroapi's Operating Cash Flow per Share or its related term are showing as below:
XPAR:EAPI'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -62.8 Med: 14 Max: 42.1
Current: 42.1
During the past 7 years, Euroapi's highest 3-Year average Operating Cash Flow per Share Growth Rate was 42.10% per year. The lowest was -62.80% per year. And the median was 14.00% per year.
XPAR:EAPI's 3-Year OCF Growth Rate is ranked better than 84.53% of 763
companies
in the Drug Manufacturers industry
Industry Median: 7.2
vs XPAR:EAPI: 42.10
Euroapi Operating Cash Flow per Share Related Terms
Euroapi Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Euroapi's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:EAPI vs ZTS, UTHR, VTRS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euroapi Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euroapi's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Euroapi's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of €1.35 mean?
Euroapi (XPAR:EAPI) has a Operating Cash Flow per Share of €1.35 as of Dec. 2025. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Euroapi and its competitors. According to the industry distribution chart, Euroapi ranks #118 out of 763 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is Euroapi's Operating Cash Flow per Share too high?
Euroapi's current Operating Cash Flow per Share is €1.35. Based on the distribution chart, Euroapi ranks #118 out of 763 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euroapi has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's Operating Cash Flow per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #118 out of 763 companies for Operating Cash Flow per Share. This places Euroapi in the top 16% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 7.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.20, based on 763 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Euroapi and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current Operating Cash Flow per Share is €1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.84, compared to a current price of €0.98 — trading 65.4% below its estimated fair value. The current Operating Cash Flow per Share is €1.35. Euroapi's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current Operating Cash Flow per Share is €1.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euroapi (XPAR:EAPI) Overvalued in 2026?
Based on GuruFocus' analysis, Euroapi stock appears to be undervalued.
The current stock price of €0.98 is trading 65.4% below its estimated GF Value™ of €2.84.
GuruFocus considers Euroapi to be Possible Value Trap.
Key valuation signals for XPAR:EAPI:
Operating Cash Flow per Share: €1.35
GF Value™: €2.84 vs. price of €0.98 (65.4% below fair value)
No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
54GF Score
Get the complete analysis for XPAR:EAPI
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:EAPI has been successfully added to your 
